Article: Viral determinants of resistance to treatment in patients with hepatitis C.
2007 Volume 20, Issue 1, Page(s) 23–38
Abstract: Chronic hepatitis C virus (HCV) infection affects more than 170 million persons worldwide and is responsible for the development of liver cirrhosis in many cases. Standard treatment with pegylated alpha interferon (IFN-alpha) in combination with the ... ...
| Abstract | Chronic hepatitis C virus (HCV) infection affects more than 170 million persons worldwide and is responsible for the development of liver cirrhosis in many cases. Standard treatment with pegylated alpha interferon (IFN-alpha) in combination with the nucleoside analogue ribavirin leads to a sustained virologic response in approximately half of the patients. IFN-alpha is classified as an indirect treatment, as it interacts with the host's immune response. The mechanism of action of ribavirin is still unknown. The benefit of triple therapy by adding other antiviral agents, e.g., amantadine, is controversial. Currently, new direct antiviral drugs (HCV protease/polymerase inhibitors) are being evaluated in phase 1/phase 2 trials. Phenotypic resistance to antiviral therapy has been attributed to amino acid variations within distinct regions of the HCV polyprotein. While sensitivity to IFN-alpha-based antiviral therapy in vivo is clearly correlated with the number of mutations within the HCV NS5A protein, the underlying functional mechanisms for this association are unknown. In turn, in vitro, several mechanisms to circumvent the host immune defense or to block treatment-induced antiviral activities have been described for different HCV proteins. By the introduction of direct antiviral drugs, hepatitis C therapy now is entering a new era in which the development of resistance may become the most important parameter for treatment success or failure. |
|||||
|---|---|---|---|---|---|---|
| MeSH term(s) | Amantadine/pharmacology ; Amantadine/therapeutic use ; Antiviral Agents/pharmacology ; Antiviral Agents/therapeutic use ; Drug Resistance, Viral/genetics ; Drug Resistance, Viral/physiology ; Hepacivirus/drug effects ; Hepatitis C/drug therapy ; Hepatitis C/virology ; Humans ; Interferon-alpha/pharmacology ; Interferon-alpha/therapeutic use ; Ribavirin/pharmacology ; Ribavirin/therapeutic use | |||||
| Chemical Substances | Antiviral Agents ; Interferon-alpha ; Ribavirin (49717AWG6K) ; Amantadine (BF4C9Z1J53) | |||||
| Language | English | |||||
| Publishing date | 2007-01 | |||||
| Publishing country | United States | |||||
| Document type | Journal Article ; Review | |||||
| ZDB-ID | 645015-5 | |||||
| ISSN | 1098-6618 ; 0893-8512 | |||||
| ISSN (online) | 1098-6618 | |||||
| ISSN | 0893-8512 | |||||
| DOI | 10.1128/CMR.00010-06 | |||||
| Shelf mark |
|
|||||
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
Full text online
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Zs.A 2409: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.